Source link : https://newshealth.biz/health-news/frontline-targeted-therapies-plus-r-chop-boosts-pfs-in-high-risk-b-cell-lymphomas/
CHICAGO — Combining two targeted therapies with standard-of-care chemotherapy extended progression-free survival (PFS) in patients with newly diagnosed B-cell lymphomas, according to data from the frontMIND trial. In the phase III study, tafasitamab (Monjuvi) and lenalidomide (Revlimid) were added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for frontline therapy in patients with untreated high-risk […]
The post Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-30 15:36:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8